MiiS (6796) reported revenue of NT$72.7 million for Oct 2026, +6.7% year on year and +7.5% from the previous month. Revenue for Jan–Oct 2026 was NT$596.7 million (+17.2% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 90 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$72.7 million | +6.7% | +7.5% |
| Sep 2026 | NT$67.6 million | +21.3% | +10.7% |
| Aug 2026 | NT$61.1 million | +24.6% | -29.4% |
| Jul 2026 | NT$86.5 million | +79.2% | +58.5% |
| Jun 2026 | NT$54.6 million | +1.0% | +3.2% |
| May 2026 | NT$52.9 million | -7.1% | -2.0% |
| Apr 2026 | NT$54 million | +24.4% | -10.6% |
| Mar 2026 | NT$60.3 million | +8.8% | +35.6% |
| Feb 2026 | NT$44.5 million | +8.1% | +4.6% |
| Jan 2026 | NT$42.6 million | +15.0% | -46.3% |
| Dec 2025 | NT$79.2 million | -32.0% | +8.4% |
| Nov 2025 | NT$73.1 million | +45.7% | +7.3% |
| Oct 2025 | NT$68.1 million | +40.3% | +22.1% |
| Sep 2025 | NT$55.7 million | +63.6% | +13.7% |
| Aug 2025 | NT$49 million | +51.6% | +1.5% |
| Jul 2025 | NT$48.3 million | +28.0% | -10.6% |
| Jun 2025 | NT$54 million | +2.7% | -5.1% |
| May 2025 | NT$56.9 million | +86.6% | +31.2% |
| Apr 2025 | NT$43.4 million | +10.1% | -21.8% |
| Mar 2025 | NT$55.5 million | +34.2% | +34.7% |
| Feb 2025 | NT$41.2 million | +119.6% | +11.3% |
| Jan 2025 | NT$37 million | +0.0% | -68.2% |
| Dec 2024 | NT$116.5 million | +118.7% | +132.3% |
| Nov 2024 | NT$50.1 million | -1.0% | +3.3% |
| Oct 2024 | NT$48.5 million | +5.1% | +42.5% |
Jan–Oct 2026 cumulative: NT$596.7 million (+17.2% YoY)
Other Biotech & Medical companies
Compare with peers: MiiS vs PEC / MiiS vs Lotus Pharm / MiiS vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16